Editorials - (2025) Volume 7, Issue 2
For over three decades, antiretroviral therapy (ART) has been the cornerstone of HIV treatment, transforming a once-lethal diagnosis into a manageable chronic condition. Yet, as science advances and the needs of people living with HIV evolve, researchers and clinicians are looking beyond viral suppression toward a more holistic and innovative therapeutic landscape. The next frontier in HIV therapeutics encompasses long-acting formulations, immune-based therapies, gene editing, and precision medicine—all aimed at improving quality of life, reducing stigma, and ultimately achieving a cure.
Abstract
For over three decades, antiretroviral therapy (ART) has been the cornerstone of HIV treatment, transforming a once-lethal diagnosis into a manageable chronic condition. Yet, as science advances and the needs of people living with HIV evolve, researchers and clinicians are looking beyond viral suppression toward a more holistic and innovative therapeutic landscape. The next frontier in HIV therapeutics encompasses long-acting formulations, immune-based therapies, gene editing, and precision medicine—all aimed at improving quality of life, reducing stigma, and ultimately achieving a cure.